• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Biogen Sales Reps Banned at Major Neurology Clinic!!!

Quote
































Good on them for doing that. This drug is a farce and everyone else who sells it(including myself), knows it. It’s a paycheck for now but if you don’t have an exit strategy you better start thinking
 




















Aduhelm is in more trouble

If it wasn’t clear just how controversial the Aduhelm approval was, a DC-based medical center made it obvious by reportedly banning all Biogen representatives from its seven offices. In a photo circulating on Twitter, The Neurology Center alluded to the growing controversy over the Alzheimer’s drug and said Biogen reps are “no longer welcome.” The company is already struggling to get the treatment off the ground, and concerns only heightened when analysts unearthed new safety data suggesting a troubling recurrence of ARIA in the small group of early commercial patients who have been dosed.
 












I remember the time when being a Drug Rep was prestigious and as long as you were not pushy and arrogant office would let you in anytime. Now, it’s an embarrassment to admit it and Management thinks you should sell something on every call.
 








"Mass General Brigham has decided that it will not provide aducanumab (Aduhelm™) for the treatment of Alzheimer’s disease at this time. Like all other drugs used within Mass General Brigham, aducanumab was subject to evaluation by the Mass General Brigham Pharmacy and Therapeutics Committee, a multidisciplinary panel of experts from across the academic health system, that serves as decision-making body to Mass General Brigham on formulary management. The evaluation included a thorough review of clinical, economic, and operational considerations. This decision was based on the current data regarding aducanumab’s safety and efficacy. We understand that this may be difficult news for some of our patients. However, we fully support continued evaluation of this medication and should new data become available we will re-evaluate this decision"
 








Top Bottom
Back
Quote